MRVI
Income statement / Annual
Last year (2024), Maravai LifeSciences Holdings, Inc.'s total revenue was $259.19 M,
a decrease of 10.30% from the previous year.
In 2024, Maravai LifeSciences Holdings, Inc.'s net income was -$144.85 M.
See Maravai LifeSciences Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$259.19 M |
$288.95 M |
$883.00 M |
$799.24 M |
$284.10 M |
$143.14 M |
$123.83 M |
| Cost of Revenue |
$150.88 M
|
$148.74 M
|
$168.96 M
|
$140.56 M
|
$79.65 M
|
$66.85 M
|
$60.77 M
|
| Gross Profit |
$108.31 M
|
$140.20 M
|
$714.04 M
|
$658.68 M
|
$204.45 M
|
$76.29 M
|
$63.07 M
|
| Gross Profit Ratio |
0.42
|
0.49
|
0.81
|
0.82
|
0.72
|
0.53
|
0.51
|
| Research and Development Expenses |
$19.22 M
|
$17.28 M
|
$18.37 M
|
$15.22 M
|
$9.30 M
|
$3.63 M
|
$4.50 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$41.19 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$161.77 M
|
$151.39 M
|
$129.26 M
|
$100.06 M
|
$94.25 M
|
$48.35 M
|
$41.19 M
|
| Other Expenses |
$162.93 M
|
$3.18 M
|
-$358,000.00
|
$279,000.00
|
-$7.47 M
|
$118,000.00
|
$87,000.00
|
| Operating Expenses |
$343.93 M
|
$171.85 M
|
$147.63 M
|
$115.28 M
|
$103.55 M
|
$51.98 M
|
$45.69 M
|
| Cost And Expenses |
$494.80 M
|
$320.59 M
|
$316.59 M
|
$255.84 M
|
$183.20 M
|
$118.83 M
|
$106.46 M
|
| Interest Income |
$27.40 M
|
$27.73 M
|
$2.34 M
|
$30.26 M
|
$30.74 M
|
$29.96 M
|
$0.00
|
| Interest Expense |
$47.70 M
|
$45.89 M
|
$20.41 M
|
$30.26 M
|
$30.74 M
|
$29.96 M
|
$27.40 M
|
| Depreciation & Amortization |
$56.87 M
|
$48.78 M
|
$38.10 M
|
$24.75 M
|
$25.84 M
|
$24.08 M
|
$22.35 M
|
| EBITDA |
-$156.92 M |
$712.41 M |
$609.99 M |
$585.78 M |
$138.27 M |
$48.19 M |
$33.25 M |
| EBITDA Ratio |
-0.61
|
2.47
|
0.69
|
0.68
|
0.33
|
0.34
|
0.32
|
| Operating Income Ratio |
-0.91
|
-0.11
|
0.65
|
0.69
|
0.24
|
0.17
|
0.13
|
| Total Other Income/Expenses Net |
-$25.87 M
|
$649.38 M
|
-$22.74 M
|
-$23.88 M
|
-$22.09 M
|
-$29.84 M
|
-$32.93 M
|
| Income Before Tax |
-$261.48 M
|
$617.74 M
|
$551.47 M
|
$530.77 M
|
$81.70 M
|
-$5.85 M
|
-$16.50 M
|
| Income Before Tax Ratio |
-1.01
|
2.14
|
0.62
|
0.66
|
0.29
|
-0.04
|
-0.13
|
| Income Tax Expense |
-$1.86 M
|
$756.11 M
|
$60.81 M
|
$61.52 M
|
$2.88 M
|
-$652,000.00
|
$417,000.00
|
| Net Income |
-$144.85 M
|
-$119.03 M
|
$490.66 M
|
$469.25 M
|
$76.89 M
|
-$5.20 M
|
-$17.73 M
|
| Net Income Ratio |
-0.56
|
-0.41
|
0.56
|
0.59
|
0.27
|
-0.04
|
-0.14
|
| EPS |
-1.05 |
-0.9 |
3.73 |
4.09 |
0.8 |
-0.0538 |
-0.2 |
| EPS Diluted |
-1.05 |
-0.9 |
1.92 |
1.82 |
0.7 |
-0.0538 |
-0.2 |
| Weighted Average Shares Out |
$137.91 M
|
$131.92 M
|
$131.54 M
|
$114.79 M
|
$96.65 M
|
$96.65 M
|
$88.97 M
|
| Weighted Average Shares Out Diluted |
$137.91 M
|
$131.92 M
|
$255.32 M
|
$257.80 M
|
$96.65 M
|
$96.65 M
|
$88.97 M
|
| Link |
|
|
|
|
|
|
|
